Sona Nanotech Arranges Brokered Private Placement Financing
Sona Nanotech Arranges Brokered Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - October 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $750,000 through a brokered private placement (the "Financing") of up to 3,750,000 units of Sona (each, a "Unit") at $0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of Sona (a "Common Share") and one-half (1/2) of a common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant will be exercisable to purchase one additional Common Share of Sona at a price of $0.30 per share for a period of 24 months from the closing date of the Financing (the "Closing Date"). Insiders and certain other existing shareholders of Sona may also subscribe for Units under the Financing.
新斯科舍省哈雷法克斯-(Newsfile Corp.-2023年10月18日)-Sona Nanotech Inc.(CSE：SONA)(OTCQB：SNANF)(The公司“，”索納“)很高興地宣佈，它計劃通過經紀私募籌集至多75萬美元。融資“)最多3,750,000單位Sona(每個，a”單位“)，每單位$0.20(”發行價“)。每個單位將由Sona的一股普通股組成(a”普通股)及普通股認購權證的一半(1/2)(每份完整認股權證，搜查令“)。每份完整的認股權證將可行使，以每股0.30美元的價格購買一股額外的Sona普通股，為期24個月，自融資結束之日起(”截止日期“)。Sona的內部人士和某些其他現有股東也可以認購融資項下的單位。
Numus Capital Corp. (the "Agent") will act as the exclusive agent for the Financing. As compensation for its services, the Agent will receive cash compensation equal to 7.5% of the gross proceeds of the Financing. The Agent will also receive non-transferable share purchase warrants (the "Broker Warrants") which will entitle the Agent to acquire such number of common shares as is equal to 7.5% of the number of Units placed by the Agent. The Broker Warrants will be exercisable at a price of $0.20 per share any time for a period of 24 months from the Closing Date. The Agent is a related party to Sona, a director of Sona being indirectly a principal shareholder of the Agent, as well such director of Sona also being a director and officer of the Agent.
Numus Capital Corp.(The座席)將作為融資的獨家代理。作為對其服務的補償，代理將獲得相當於融資總收益7.5%的現金補償。代理還將獲得不可轉讓的認股權證(經紀人認股權證“)，使代理人有權取得相等於代理人配售的單位數目的7.5%的普通股數目。經紀認股權證將可隨時按每股0.2美元的價格行使，由完成日期起計24個月內。代理人是SONA的關聯方，而SONA的董事間接為代理人的主要股東，而SONA的董事亦為董事及代理人的高級人員。
Sona intends to use the net proceeds of the Financing for further research and development of its Targeted Hyperthermia TherapyTM ("THT"), as well as for general working capital purposes.
Sona打算將融資所得淨額用於其靶向熱療療法的進一步研發TM(“THT”)，以及一般營運資金用途。
Completion of the Financing is subject to the satisfaction of certain conditions, and all securities issued pursuant to the Financing will be subject to a hold-period of four months and a day commencing from the Closing Date.
融資的完成取決於某些條件的滿足，根據融資發行的所有證券將受到自成交日期起計四個月零一天的持有期的限制。
Contact:
聯繫方式：
David Regan, CEO
+1-902-536-1932
david@sonanano.com
首席執行官David·裡根
+1-902-536-1932
郵箱：David@sonanano.com
About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (44°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona's initial clinical target is colorectal cancer.
關於索納納米技術公司
納米技術生命科學公司Sona Nanotech正在開發靶向熱療，這是一種光熱癌症療法，使用治療性熱能治療實體癌腫瘤。熱通過紅外光傳遞到腫瘤，紅外光被腫瘤中的Sona金納米棒吸收，並以熱的形式重新發射。治療熱(44°C)刺激免疫系統，縮小腫瘤，滅活腫瘤幹細胞，增加腫瘤灌注量，從而使藥物能夠更有效地到達所有腫瘤隔室。納米棒的大小、形狀和表面化學作用於實體腫瘤滲漏的血管系統，而腫瘤組織的選擇性熱敏感性使治療能夠提供乾淨的邊緣。靶向熱療有望安全、有效、微創、成本具有競爭力，是藥物治療和其他癌症治療的有價值的輔助手段。索納最初的臨床目標是結直腸癌。
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
Sona已經開發了多種製造金納米顆粒的專利方法，用於開發癌症治療和診斷測試平臺。Sona Nanotech的金納米棒顆粒不含十六烷基三甲基銨(CTAB)，消除了在醫療應用中使用其他金納米棒技術所帶來的毒性風險。預計索納的金納米技術可能會被改裝用於應用，作為一種安全有效的多種醫療治療的輸送系統，但需要得到包括加拿大衛生部和FDA在內的各種監管機構的批准。
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications of Targeted Hyperthermia Therapy, Sona's preclinical study plans, the potential impact of the planned studies and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
有關前瞻性資訊的警告性聲明：本新聞稿包括適用於加拿大證券法的某些“前瞻性聲明”，包括有關靶向熱療療法的預期應用、Sona的臨床前研究計劃、計劃研究的潛在影響及其產品開發計劃的聲明。前瞻性陳述必須基於一系列假設或估計，雖然這些假設或估計被認為是合理的，但會受到已知和未知的風險、不確定性和其他因素的影響，這些風險、不確定性和其他因素可能會導致實際結果和未來事件與此類前瞻性陳述明示或暗示的結果大不相同，包括Sona可能無法成功獲得足夠的臨床和其他數據以提交監管報告、籌集足夠的額外資本或開發預期的治療方法，以及THT可能被證明沒有目前預期的好處。不能保證這些陳述將被證明是準確的，因為實際結果和未來事件可能與這些陳述中預期的大不相同。因此，讀者不應過分依賴前瞻性陳述。除非法律要求，否則SONA不會因為新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述，也不承擔任何義務。
Not for distribution to United States newswire services or for dissemination in the United States
不得分發給美國通訊社或在美國境內傳播
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。